Antiviral drugs

PreclinicalSmall molecule

SSocietà Italiana Talassemie ed Emoglobinopatie

Antiviral drugs is one of 49 small molecule programs targeting Hepatitis C Virus Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis C Virus InfectionActive, not recruiting

Hepatitis C Virus InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Hepatitis C Virus Infection

#DrugCompanyPhaseTrials

Avelox

Lexapro

Actos

Sovaldi

6 5

Mifeprex

DDanco

Approved

—6

Januvia

ZZydus Therapeutics Inc.

Approved

—7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Promacta

Olysio

3 10

Ombitasvir/paritaprevir/ritonavir

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C Virus Infection1 trial

Hepatitis C Virus Infection in Patients With Hemoglobinopathies

Completed·SSocietà Italiana Talassemie ed Emoglobinopatie··NCT03149289·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antiviral drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiviral drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiviral drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Società Italiana Talassemie ed Emoglobinopatie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSocietà Italiana Talassemie ed Emoglobinopatie

Antiviral drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C Virus Infection1 trial

References

Drug Info

Quick Facts

Related News